Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
- 13 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2022.
- 22 Nov 2016 New trial record